Safety and Immunogenicity of a Subunit Trivalent Influenza Vaccine, Northern Hemisphere Formulation 2013/2014, Including MF59C.1 Adjuvant, in Healthy Adults ≥65 Years of Age
Condition: Human Influenza
MeSH terms: Influenza, Human
Intervention: aTIV
Intervention description: Adjuvanted Trivalent Influenza Virus Vaccine (surface antigen, inactivated, adjuvanted with MF59C.1, egg-derived)
Phase: Phase 2
Study type: Interventional
Primary purpose: Prevention
Allocation: Non-Randomized
Intervention model: Single Group Assignment
Masking: None (Open Label)
Enrollment: 63.0
Sex: All
Minimum age: 65 Years
Healthy volunteers: Accepts Healthy Volunteers
Keywords: Influenza,; Elderly,; Immunology,; Safety

Summary:

      The present study is designed to confirm the safety and immunogenicity of trivalent, surface
      antigen, inactivated influenza vaccine including MF59C.1 adjuvant, formulation 2013/2014
      Northern Hemisphere, in adults ≥65 years of age.

      For the immunogenicity endpoints the antibody response to each influenza vaccine antigen,
      will be measured by means of Single Radial Hemolysis (SRH) or Hemagglutination Inhibition
      (HI) at approximately 21 days post immunization.

      The vaccine composition will be based on the World Health Organization (WHO) recommended
      influenza strains for 2013/2014 Northern Hemisphere.

      The results of this study are intended to support the use of this vaccine in future influenza
      seasons if the recommended vaccine composition remains the same, in compliance with the
      requirements of the current European Union (EU) recommendations for clinical trials related
      to yearly licensing of influenza vaccines.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Male or female volunteers aged 65 years or older, mentally competent, who gave written
             informed consent prior to study entry;

          -  Were able to comply with all the study requirements; and

          -  Were in good health as determined by the outcome of medical history, physical
             examination, and clinical judgment of the investigator.

        Exclusion Criteria:

          -  Had behavioral or cognitive impairment or psychiatric disease that, in the opinion of
             the investigator, may have interfered with the subject's ability to participate in the
             study;

          -  Had a serious chronic or acute disease (in the judgment of the investigator)
             including, but not limited to:

               -  medically significant cancer (except for benign or localized skin cancer, cancer
                  in remission for >= 10 years, or localized prostate cancer that has been
                  clinically stable for > 2 years without treatment)

               -  medically significant advanced congestive heart failure (ie, New York Heart
                  Association [NYHA] class III and IV)

               -  chronic obstructive pulmonary disease (ie, Global initiative for chronic
                  Obstructive Lung Disease [GOLD] stage III and IV)

               -  autoimmune disease (including rheumatoid arthritis and excepting Hashimoto's
                  thyroiditis that has been clinically stable for >= 5 years)

               -  diabetes mellitus type I

               -  poorly controlled diabetes mellitus type II

               -  advanced arteriosclerotic disease

               -  history of underlying medical condition such as major congenital abnormalities
                  requiring surgery, chronic treatment, or associated with developmental delay (eg,
                  Down's syndrome)

               -  acute or progressive hepatic disease

               -  acute or progressive renal disease

               -  severe neurological (especially Guillain-Barré syndrome) or psychiatric disorder

               -  severe asthma

          -  Had a history of any anaphylactic reaction and/or serious allergic reaction to any
             component of the study vaccine.

          -  Had a known or suspected (or have a high risk of developing) impairment/alteration of
             immune function (excluding that normally associated with advanced age) resulting, for
             example, from:

               -  receipt of immunosuppressive therapy (any parenteral or oral corticosteroid or
                  cancer chemotherapy/radiotherapy) within the past 60 days and for the full length
                  of the study,

               -  receipt of immunostimulants within the past 6 months,

               -  receipt of parenteral immunoglobulin preparation, blood products, and/or plasma
                  derivates within the past 3 months and for the full length of the study, or

               -  suspected or known human immunodeficiency virus (HIV) infection or HIV related
                  disease.

          -  Had known or suspected drug or alcohol abuse within the past 2 years;

          -  Had bleeding diathesis or conditions associated with prolonged bleeding time that, in
             the investigator's opinion, would have interfered with the safety of the subject;

          -  Was not able to comprehend and to follow all required study procedures for the whole
             period of the study;

          -  Had a history or any illness that, in the opinion of the investigator, would have
             posed additional risk to the subjects because of participation in the study;

          -  Had the following within the past 6 months:

               -  any laboratory confirmed seasonal or pandemic influenza disease,

               -  received any seasonal or pandemic influenza vaccine.

          -  Had received any other vaccine within 4 weeks prior to enrollment in this study or who
             were planning to receive any vaccine during the study;

          -  Had acute or chronic infections requiring antiviral therapy within the last 7 days;

          -  Had experienced fever (ie, body temperature [preferably oral] >= 38.0°C) within the
             last 3 days of intended study vaccination;

          -  Had been participating in any clinical trial with another investigational product 4
             weeks prior to first study visit or intended to participate in another clinical study
             at any time during the conduct of this study;

          -  Was part of study personnel or had close family members conducting this study;

          -  Had a body mass index (BMI) >35 kg/m2 (BMI is calculated by dividing the subject's
             weight in kilograms by the subject's height in meters multiplied by the subject's
             height in meters)